Bristol-Myers Squibb Co at Raymond James Institutional Investors Conference (Virtual) Transcript
Greetings, everyone. Welcome to the 42nd Annual Raymond James Institutional Investor Conference, the second day that's starting right now. Thank you all for joining. My name is Dane Leone. I'm one of the senior biotech analysts with Raymond James. This session, I will be discussing the outlook for Bristol-Myers Squibb and joined by David Elkins, who is the Executive Vice President, Chief Financial Officer. Very excited to have David and his team joining us today for this discussion.
David, good morning to you. Thank you very much for joining us for this session today.
Dane, thank you for having me. It's a pleasure to be here.
Great. So the format for this discussion for everyone joining us, we're going to go through a fireside chat together. As the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
